The Technical Analyst
Apellis Pharmaceuticals [APLS]
Exchange: Nasdaq Global Select Sector: Healthcare Industry: Biotechnology
Apellis Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
0.68% $39.72
Last updated: 16 May 2022 @ 11:19 am
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 4 231.05 mill |
| EPS: | -8.84 |
| P/E: | 0.000 |
| Earnings Date: | Aug 08, 2022 |
| SharesOutstanding: | 106.52 mill |
| Avg Daily Volume: | 1.214 mill |
| RATING 2022-05-13 |
|---|
| B |
| Neutral |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | n/a | |||||
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$48.24 (21.44%) $8.52 |
| Date: 2022-05-16 |
| True Range Average |
|---|
|
+/- $3.39 ( +/- 8.60%) Range: 36.06 - 42.84 |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-05-02 | Grossi Federico | Sell | 11 250 | Stock Option (Right to Buy) |
| 2022-05-02 | Grossi Federico | Sell | 2 500 | Common Stock |
| 2022-04-29 | Deschatelets Pascal | Sell | 4 000 | Stock Option (Right to Buy) |
| 2022-04-29 | Deschatelets Pascal | Sell | 11 250 | Stock Option (Right to Buy) |
| 2022-04-29 | Deschatelets Pascal | Sell | 4 000 | Common Stock |
| INSIDER POWER |
|---|
| 59.75 |
| Last 100 transactions |
| Buy: 912 259 | Sell: 203 897 |
Forecast:
12:58 - $39.92
Live Trading Signals (every 1 min)
Forecast
1: 11:28 - $39.52
Forecast 2: 12:18 - $39.63
Forecast 3: 12:58 - $39.92
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $39.72 (0.68% ) |
| Volume | 0.232 mill |
| Avg. Vol. | 1.214 mill |
| % of Avg. Vol | 19.08 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For APLS
141 Signals | Accuracy: 22.70% | Accuracy Buy: 18.57% | Accuracy Sell: 26.76%
Avg return buy: 0.03 % | Avg return sell: -0.37 %
$1 invested is now $1.01 or 1.00% since 20-04-22
| Date | Signal | @ | Closed | % | May 16 - 11:02 | sell | $39.67 | $39.71 @ May 16 - 11:04 | 0.10% |
|---|---|---|---|---|
| May 16 - 10:31 | buy | $39.59 | $39.49 @ May 16 - 11:01 | -0.25% |
| May 16 - 09:31 | sell | $39.18 | $39.94 @ May 16 - 10:30 | 1.94% |
| May 13 - 16:51 | buy | $39.45 | $39.18 @ May 16 - 09:30 | -0.68% |
| May 13 - 16:21 | sell | $39.45 | $39.45 @ May 13 - 16:51 | 0.00% |
| May 13 - 15:59 | buy | $39.45 | $39.45 @ May 13 - 16:20 | 0.00% |
| May 13 - 15:57 | sell | $39.39 | $39.42 @ May 13 - 15:58 | 0.06% |
| May 13 - 15:51 | buy | $39.43 | $39.35 @ May 13 - 15:53 | -0.20% |
| May 13 - 15:48 | sell | $39.24 | $39.41 @ May 13 - 15:50 | 0.43% |
| May 13 - 15:44 | buy | $39.48 | $39.34 @ May 13 - 15:47 | -0.37% |
APLS
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin disease, C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company is also developing APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration. Apellis Pharmaceuticals, Inc. has a strategic collaboration with Swedish Orphan Biovitrum AB (publ) for the advancement of pegcetacoplan, a C3 therapy for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. The company was founded in 2009 and is based in Waltham, Massachusetts.
Latest Press Releases
2022-05-12 11:05:00 - Press Release
Apellis Announces Seven Abstracts In Pnh To Be Presented At The European Hematology Association Congress
Waltham, mass., may 12, 2022 (globe newswire) -- apellis pharmaceuticals, inc. (nasdaq: apls), a global biopharmaceutical company and leader in complement, today announced that seven abstracts will be presented at the hybrid european hematology association (eha) congress to be held june 9-12 in vienna, austria. data to be presented reinforce the robust efficacy and safety profile of empaveli® (pegcetacoplan) for the treatment of paroxysmal nocturnal hemoglobinuria (pnh).
2022-05-06 16:23:00 - Press Release
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Waltham mass., may 06, 2022 (globe newswire) -- apellis pharmaceuticals, inc. (nasdaq: apls), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to four new employees with a grant date of may 2, 2022, as equity inducement awards outside of the company's 2017 stock incentive plan (but under the terms of the 2022 inducement stock incentive plan) and material to the employees' acceptance of employment with the company. the equity awards were approved in accordance with nasdaq listing rule 5635(c)(4).
2022-05-02 15:30:00 - Press Release
Apellis Announces Detailed 18-month Results From Phase 3 Derby And Oaks Studies Of Pegcetacoplan For Geographic Atrophy (ga) At Arvo Annual Meeting
Waltham, mass., may 02, 2022 (globe newswire) -- apellis pharmaceuticals, inc. (nasdaq: apls), a global biopharmaceutical company and leader in complement, today announced detailed, longer-term data from the phase 3 derby and oaks studies of intravitreal pegcetacoplan, an investigational, targeted c3 therapy, for the treatment of geographic atrophy (ga) secondary to age-related macular degeneration (amd).
2022-04-21 07:00:00 - Press Release
Apellis Announces Results From New Global Survey Conducted By The Harris Poll Revealing The Emotional Burden And Impact On Independence Caused By Geographic Atrophy (ga)
Waltham, mass., april 21, 2022 (globe newswire) -- apellis pharmaceuticals, inc. (nasdaq: apls), a global biopharmaceutical company and leader in complement, today announced results from a global survey conducted by the harris poll, which found that living with geographic atrophy (ga) can cause a substantial emotional burden and impact on independence. ga is a leading cause of blindness that affects more than 5 million people worldwide, including one million people in the united states.1,2
2022-03-28 16:01:00 - Press Release
Apellis Pharmaceuticals Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares
Waltham, mass., march 28, 2022 (globe newswire) -- apellis pharmaceuticals, inc., (nasdaq:apls), a global biopharmaceutical company and leader in complement, today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,117,021 shares at the public offering price of $47.00 per share. the exercise of the option to purchase additional shares brought the total number of shares of common stock sold by apellis to 8,563,830 shares and increased the amount of gross proceeds, before deducting underwriting discounts and commissions and expenses payable by apellis, to $402...
Latest News
2022-05-06 11:20:11 - Zacks Investment Research
Apellis (APLS) Hit By Wider-Than-Expected Q1 Loss, Revenues Top
Apellis' (APLS) earnings missed estimates in the first quarter of 2022, while revenues surpassed expectations.
2022-05-05 16:05:00 - GlobeNewsWire
Apellis Pharmaceuticals to Present at the Bank of America Securities 2022 Healthcare Conference
WALTHAM, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will present at the Bank of America Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 8:40 a.m. PT .
2022-05-04 21:05:22 - Seeking Alpha
Apellis Pharmaceuticals, Inc. (APLS) CEO Cedric Francois on Q1 2022 Results - Earnings Call Transcript
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Meredith Kaya - SVP, IR & Strategic Finance Adam Townsend - Chief Commercial Officer Cedric Francois - Co-Founder, President, CEO & Director Timothy Sullivan - CFO & Treasurer Federico Grossi - Chief Medical Officer Conference Call Participants Madhu Kumar - Goldman Sachs Group Jonathan Miller - Evercore ISI Joseph Stringer - Needham & Company Philip Nadeau - Cowen and Company Eliana Merle - UBS Timur Ivannikov - Raymond James & Associates Derek Archila - Wells Fargo Securities Yigal Nochomovitz - Citigroup Laura Chico - Wedbush Securities Colleen Kusy - Robert W. Baird & Co...
2022-04-26 07:00:00 - GlobeNewsWire
Apellis Pharmaceuticals to Host Conference Call on May 4, 2022 to Discuss First Quarter 2022 Financial Results
WALTHAM, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will host a conference call and webcast to discuss its first quarter 2022 financial results on Wednesday, May 4, 2022 at 4:30 p.m. ET.
2022-04-22 15:03:22 - Zacks Investment Research
Apellis (APLS) Thrives on Empaveli, Stiff Competition a Woe
Apellis' (APLS) marketed drug, Empaveli, is approved for treating paroxysmal nocturnal hemoglobinuria. The drug's label expansion studies hold promise.
2022-03-30 12:47:47 - Zacks Investment Research
Why Is Apellis Pharmaceuticals, Inc. (APLS) Up 8.9% Since Last Earnings Report?
Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock?
2022-03-23 16:33:05 - Benzinga
Why Apellis Pharmaceuticals Stock Is Falling After Hours
Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares are trading lower in Wednesday's after-hours session after the company announced a proposed public offering of $300 million of its common stock. All of the shares are being offered by Apellis.
2022-03-16 11:59:07 - Benzinga
Apellis' Pegcetacoplan Showed Continuous, Meaningful Effects At Month 18 In Geographic Atrophy Studies
Apellis Pharmaceuticals Inc (NASDAQ: APLS) announced longer-term data from the Phase 3 DERBY and OAKS studies, which showed that intravitreal pegcetacoplan continued to reduce geographic atrophy (GA) lesion growth. These data will be included in the U.S. marketing application that the.
2022-03-16 10:07:02 - Benzinga
Here's Why Apellis Pharmaceuticals Shares Are Rising
Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares are trading higher by 8.6% at $43.49 after the company announced Pegcetacoplan showed continuous and clinically meaningful effects at month 18 in Phase 3 Derby and Oaks studies for geographic atrophy. Apellis Pharmaceuticals says, at month 18,.
2022-03-16 08:10:09 - Market Watch
Apellis shares jump 6% after the company announces new new data for its geographic atrophy drug
Shares of Apellis Pharmaceuticals Inc. APLS, +1.55% gained 6.1% in premarket trading on Wednesday after the company shared longer-term clinical data demonstrating that intravitreal pegcetacoplan reduced geographic atrophy lesion growth at 18 months. The data, culled from two clinical trials, will be used in the new drug application that is expected to be submitted to the Food and Drug Administration in the second quarter of this year.